(NASDAQ: PCSA) Processa Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.43%.
Processa Pharmaceuticals's earnings in 2025 is -$12,933,604.On average, 4 Wall Street analysts forecast PCSA's earnings for 2025 to be -$24,266,386, with the lowest PCSA earnings forecast at -$23,869,876, and the highest PCSA earnings forecast at -$24,385,339. On average, 4 Wall Street analysts forecast PCSA's earnings for 2026 to be -$11,266,536, with the lowest PCSA earnings forecast at -$13,322,722, and the highest PCSA earnings forecast at -$8,921,465.
In 2027, PCSA is forecast to generate -$12,133,193 in earnings, with the lowest earnings forecast at -$11,657,382 and the highest earnings forecast at -$12,490,052.